Matthew R. Renna Managing Partner

“Pharma and Biotech R&D productivity is finally on the rise, yielding exciting new product cycles to drive industry growth. Couple that with a resurgence in M&A activity to leverage existing infrastructure, and we are seeing tremendous opportunities to generate investment returns within the therapeutics space.”

Matthew R. Renna

Managing Partner

Matthew joined Westfield Capital in 2013 as a member of the Investment Committee covering the Health Care sector. Previously he was with Vinik Asset Management as a Health Care Portfolio Manager.

His professional experience also includes Director, SMID Growth Equity team at BlackRock, Inc., Senior Equity Analyst at RA Capital Management and Director, Healthcare/Biotechnology at Soleil Securities Corporation, Neponset Equity Research. Matthew began his career in the Health Care industry at Merck & Co., before entering equity research as a Senior Research Associate covering Specialty Pharmaceuticals at Leerink Swann LLC.

Matthew earned a Master’s in Business Administration from The Carroll School of Management at Boston College and a Master’s of Science from Boston University. He earned his Bachelor of Science from Boston University where he graduated magna cum laude.

In his free time, Matthew enjoys golf, reading and spending time with his wife and three children.

Professional History

Managing Partner
Biopharma, Life Sciences, Tools

2013 - Present: Westfield Capital Management
2012 - 2013: Vinik Asset Management
2009 - 2012: BlackRock, Inc.
2008 - 2009: RA Capital Management
2005 - 2008: Soleil Securities Corporation
2004 - 2005: Leerink Swann LLC
2001 - 2004: Merck & Co., Inc.
2006: Boston College, Carroll School of Management, MBA
2001: Boston University, MS
1999: Boston University, BS

Clients listed here were chosen as generally representative of the types of clients that comprise Westfield Capital Management's institutional client base and were not chosen based on performance-based criteria.
It is not known whether these clients approve or disapprove of the adviser or the advisory services provided